Lilly Signs Cardiovascular Research Partnership With India’s Zydus Cadila
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal worth a potential $300 million in milestone payments gives Lilly option to license up to six cardiometabolic or dyslipidemia compounds.